modulates other steps during transcription. properties and a novel binding mode, whereby a bridging interaction via a water mol.
role in specifying the subdomain fold by acting as gatekeeper residues. Comparison of the structures of protein kinase domains, both alone and in complexes, allows generalizations to be made about the mechanisms that regulate protein kinase activation. From Starfish Oocytes to Clinical Trialshttps://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1Oksro%253D&md5=3ec20ced62696bde94a8fc06b5da7e29Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomerSynthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomerhttps://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1GktLg%253D&md5=33477735c9cd729ce893171d82a04419In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVOksL4%253D&md5=bf8ed57667ec566b9cc11c27158f6b8bIn vitro activity of cyclin-dependent kinase inhibitor CYC202 (seliciclib, In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomasAnnals of oncology : official journal of the European Society for Medical Oncologyhttps://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzhsV2qtw%253D%253D&md5=879f9b6f728ee343bf8e6b99b06da471Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II-Dependent Transcription and Down-regulation of Mcl-1https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFels7w%253D&md5=53ea7c574a6edba6932e5e4d1565cc85Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitorsImidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitorshttps://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Cqs7zM&md5=c2967070f2ab5480c2fddb111a18687bDiscovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activityDiscovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), A Potent and Selective Cyclin-Dependent Kinase Inhibitor with Significant in Vivo Antitumor Activityhttps://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVWku77N&md5=9101e72b5f22a961e9c42b65e453e196In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trialsIn vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trialshttps://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1els7nM&md5=ce7c9fc59ec7e500778035b4a9103bf5Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Designhttps://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVGisLg%253D&md5=c90f8cc1f958002a2116e35795b110eehttps://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aecDiscovery and characterization of 2-anilino-4-(thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agentsDiscovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agentshttps://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtLfL&md5=08aff2706f6eda4ba1038327267a361eThe CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVGlsro%253D&md5=32dc86d1d1b8ff619446a4d6a6773341Hole, A. J.; Baumli, S.; Shao, H.; Shi, S.; Huang, S.; Pepper, C.; Fischer, P. M.; Wang, S.; Endicott, J. All mutants are less stable than DM HP36, but all are well folded as judged by CD and 1H NMR.